Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-23-007386
Filing Date
2023-05-01
Accepted
2023-05-01 06:47:27
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A plx-20221231x10ka.htm   iXBRL 10-K/A 442487
2 EX-31.1 plx-20221231xex31d1.htm EX-31.1 5568
3 EX-31.2 plx-20221231xex31d2.htm EX-31.2 5295
  Complete submission text file 0001558370-23-007386.txt   714497

Data Files

Seq Description Document Type Size
4 EX-101.SCH plx-20221231.xsd EX-101.SCH 4100
5 EX-101.DEF plx-20221231_def.xml EX-101.DEF 31531
6 EX-101.LAB plx-20221231_lab.xml EX-101.LAB 20212
7 EX-101.PRE plx-20221231_pre.xml EX-101.PRE 16947
9 EXTRACTED XBRL INSTANCE DOCUMENT plx-20221231x10ka_htm.xml XML 8371
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-33357 | Film No.: 23869848
SIC: 2836 Biological Products, (No Diagnostic Substances)